Early data: it depends on indications. Early data are pretty much indicative of future efficacy for lab parameter based efficacy like HCV and diabetes, unlike subjective measure of efficacy or surrogate measure of efficacy. As of long term efficacy and safety, they can only be known once tested in larger and longer trial.
Glucokinase for T2D is a promising target. Almost every big pharma in diabetes space have candidates in clinic now. Diabetes don't generate buzz like oncology, HCV, orphan disease these days. Based on my understanding of the target, I think some will come out of this target even if some of current ones have some safety issues, they can be further optimized which ARRY and AMGN agreement include. Here are a few candidates from a few years ago, not much have changed since:
Market Data 
Markets 
AI
